ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RSV/hMPV_V low dose vaccine

Also written as “RSV/hMPV_V medium dose vaccine”, “RSV/hMPV_V high dose vaccine” and “RSV/hMPV_W low dose vaccine”.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by GlaxoSmithKline.

Furthest: phase 2, since May 26, 20261 company-led study, 1 open or runningNext primary completion: Apr 5, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline11 open or runningphase 2since May 26, 2026May 26, 2026Apr 5, 2029phase 2 · NCT07628049

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2026First study: phase 2 study in Respiratory Syncytial Virus Infections+MetapneumovirusFirst studyNCT07628049 · 1,456 planned · United States, Australia

Ahead

  1. Apr 5, 2029Primary completion: phase 2 study in Respiratory Syncytial Virus Infections+MetapneumovirusNCT07628049

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“RSV/hMPV_V low dose vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07628049Respiratory Syncytial Virus Infections+Metapneumovirus · United States, Australia2RecruitingApr 5, 20291,456

How it is read

Names in the registry

  • “RSV/hMPV_V low dose vaccine”, 1 entry
  • “RSV/hMPV_V medium dose vaccine”, 1 entry
  • “RSV/hMPV_V high dose vaccine”, 1 entry
  • “RSV/hMPV_W low dose vaccine”, 1 entry
  • “RSV/hMPV_W medium dose vaccine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.